1
|
Huang X, An X, Gao X, Wang N, Liu J, Zhang Y, Qi G, Zhang C. Serum amyloid A facilitates expansion of CD4 + T cell and CD19 + B cell subsets implicated in the severity of myasthenia gravis patients. J Neurochem 2024; 168:224-237. [PMID: 38214332 DOI: 10.1111/jnc.16047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2023] [Revised: 12/12/2023] [Accepted: 12/29/2023] [Indexed: 01/13/2024]
Abstract
Serum amyloid A (SAA) is a clinically useful inflammatory marker involved in the pathogenesis of autoimmune diseases. This study aimed to explore the SAA levels in a cohort of patients with myasthenia gravis (MG) in relation to disease-related clinical parameters and myasthenic crisis (MC) and elucidate the effects of SAA on immune response. A total of 82 MG patients including 50 new-onset MG patients and 32 MC patients were enrolled in this study. Baseline data and laboratory parameters of all enrolled MG patients were routinely recorded through electronic medical systems. SAA levels were measured by enzyme-linked immunosorbent assay (ELISA) kit. CD4+ T and CD19+ B cell subsets were analyzed by flow cytometry. In vitro, human recombinant SAA (Apo-SAA) was applied to stimulate peripheral blood mononuclear cells (PBMCs) from MG patients to observe the effect on T and B cell differentiation. Our results indicated that SAA levels in new-onset MG patients were higher than those in controls and were positively correlated with QMG score, MGFA classification, plasmablast cells, IL-6, and IL-17 levels. Subgroup analysis revealed that SAA levels were increased in generalized MG (GMG) patients than in ocular MG (OMG), as well as elevated in late-onset MG (LOMG) than in early-onset MG (EOMG) and higher in MGFA III/IV compared with MGFA I/II. The ROC curve demonstrated that SAA showed good diagnostic value for MC, especially when combined with NLR. In vitro, Apo-SAA promoted the Th1 cells, Th17 cells, plasmablast cells, and plasma cells differentiation in MG PBMCs. The present findings suggested that SAA was increased in MG patients and promoted expansion of CD4+ T cell and CD19+ B cell subsets, which implicated in the severity of MG patients.
Collapse
Affiliation(s)
- Xiaoyu Huang
- Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China
| | - Xueting An
- Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China
| | - Xue Gao
- Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China
| | - Ningning Wang
- Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China
| | - Jia Liu
- Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China
| | - Yong Zhang
- Department of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
| | - Guoyan Qi
- Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, Shijiazhuang, Hebei Province, China
| | - Chao Zhang
- Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China
| |
Collapse
|
2
|
Jin M, Liu P, Qi G. Exploring Potential Biomarkers of Early Thymoma based on Serum Proteomics. Protein Pept Lett 2024; 31:74-83. [PMID: 38053354 DOI: 10.2174/0109298665275655231103105924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Revised: 09/25/2023] [Accepted: 10/06/2023] [Indexed: 12/07/2023]
Abstract
BACKGROUND Early diagnosis remains difficult because the early symptoms of thymoma are atypical. OBJECTIVES This study aimed to analyze the changes of serum proteins in the early stage of thymoma (stage I/II) by proteomics method and to screen and validate candidate biomarkers. METHODS Proteins were extracted from 8 sera patients with stage I/II thymoma and 9 healthy controls. The levels of serum proteins were detected by data-independent acquisition (DIA) quantitative proteomics techniques, and the differential proteins were identified. The proteomic results were verified by enzyme-linked immunosorbent assay. Additionally, differentially expressed proteins were analyzed using receiver operating characteristic curves (ROC). RESULTS There were 80 differentially expressed proteins between the patients with thymoma and the healthy control group, among which 39 were up-regulated and 41 were down-regulated. Differential protein enrichment is involved in environmental information processing, signaling molecules and interactions, and in the body system and the immune system. The analysis of receptor working characteristic curves showed that the areas under the curve of CORO1A, SAA1 and LTA4H were all larger than 0.8, indicating that these proteins had good diagnostic value. CONCLUSION CORO1A, SAA1 and LTA4H may be new biomarkers for early screening of thymoma.
Collapse
Affiliation(s)
- Min Jin
- Department of Oncology, Hebei Medical University, Hebei, China
- People's Hospital of Shijiazhuang Affiliated to Hebei Medical University, Hebei, China
| | - Peng Liu
- People's Hospital of Shijiazhuang Affiliated to Hebei Medical University, Hebei, China
| | - Guoyan Qi
- Department of Oncology, Hebei Medical University, Hebei, China
- People's Hospital of Shijiazhuang Affiliated to Hebei Medical University, Hebei, China
- Hebei Provincial Key Laboratory of Myasthenia Gravis, Hebei, China
- Hebei Provincial Clinical Research Center for Myasthenia Gravis, Hebei, China
| |
Collapse
|
3
|
Li Y, Yang Q, Liu Y, Yi H, Ju Y, Qi G. POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma. Invest New Drugs 2023; 41:556-563. [PMID: 37318657 DOI: 10.1007/s10637-023-01375-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2023] [Accepted: 06/02/2023] [Indexed: 06/16/2023]
Abstract
Precise selection of patients who could benefit from immune checkpoint inhibitors (ICIs) is an important challenge for immunotherapy in lung cancer. POTEE (POTE Ankyrin Domain Family Member E) is a member of one primate-specific gene family which have been identified as cancer-related antigens and potential target for immunotherapy of cancer. Here, we investigated the correlation between POTEE mutation and the clinical outcome of ICIs treatment in non-small cell lung cancer (NSCLC). We merged three NSCLC cohorts (n = 165) to assess predictive value of POTEE mutation of immunotherapy efficacy in NSCLC. The prognostic analysis and the potential molecular mechanism exploration were conducted based on the data from The Cancer Genome Atlas (TCGA) database. In the merged cohort, patients with POTEE-mutation (POTEE-Mut) had a significantly higher objective response rate (ORR) (100% vs 27.7%; P < 0.001) and longer progression-free survival (PFS) (P = 0.001; HR 0.08; 95% CI 0.01 - 0.54) compared to patients with POTEE wild-type (POTEE-WT) in NSCLC. Also, patients with POTEE-Mut showed higher ORR (100% vs 27.2%; P < 0.001) and longer PFS (P = 0.001; HR 0.07; 95% CI 0.01 - 0.52) in lung adenocarcinoma (LUAD). POTEE mutation was significantly associated with higher tumor mutational burden (TMB) and higher neoantigen load (NAL), but not with PD-L1 expression in LUAD. Gene set enrichment analyses (GSEA) analysis revealed prominent enrichment of signatures related to DNA repair in POTEE-Mut group (P < 0.001) in LUAD. Our results indicate that POTEE mutation could serve as a potential predictive biomarker for ICIs in LUAD. However, prospective cohort studies are still needed for further validation.
Collapse
Affiliation(s)
- Yongzhao Li
- Center of Treatment of Myasthenia Gravis, Hebei Provincial Key Laboratory of Myasthenia Gravis, Hebei Provincial Clinical Research Center for Myasthenia gravis, People's Hospital of Shijiazhuang affiliated to Hebei Medical University, Hebei, 050000, Shijiazhuang, China
| | - Qidong Yang
- The Medical Department, The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd; Nanjing Simcere Medical Laboratory Science Co., Ltd, Jiangsu, 210002, Nanjing, China
| | - Yaqin Liu
- The Medical Department, The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd; Nanjing Simcere Medical Laboratory Science Co., Ltd, Jiangsu, 210002, Nanjing, China
| | - Huan Yi
- The Medical Department, The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd; Nanjing Simcere Medical Laboratory Science Co., Ltd, Jiangsu, 210002, Nanjing, China
| | - Yongzhi Ju
- The Medical Department, The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd; Nanjing Simcere Medical Laboratory Science Co., Ltd, Jiangsu, 210002, Nanjing, China
| | - Guoyan Qi
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang affiliated to Hebei Medical University, Hebei, 050000, Shijiazhuang, China.
| |
Collapse
|
4
|
Li J, Qi G, Liu Y. Proteomics analysis of serum from thymoma patients. Sci Rep 2023; 13:5117. [PMID: 36991043 PMCID: PMC10060243 DOI: 10.1038/s41598-023-32339-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2022] [Accepted: 03/26/2023] [Indexed: 03/31/2023] Open
Abstract
Thymoma is the most common malignant tumor in thymic epithelial tumors (TETS). This study aimed to identify the changes in serum proteomics in patients with thymoma. Proteins were extracted from twenty patients with thymoma serum and nine healthy controls and prepared for mass spectrometry (MS) analysis. Data independent acquisition (DIA) quantitative proteomics technique was used to examine the serum proteome. Differential proteins of abundance changes in the serum were identified. Bioinformatics was used to examine the differential proteins. Functional tagging and enrichment analysis were conducted using the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. The string database was used to assess the interaction of different proteins. In all, 486 proteins were found in all samples. There were differences in 58 serum proteins between patients and healthy blood donors, 35 up-regulated and 23 down-regulated. These proteins are primarily exocrine and serum membrane proteins involved in controlling immunological responses and antigen binding, according to GO functional annotation. KEGG functional annotation showed that these proteins play a significant role in the complement and coagulation cascade and the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signal pathway. Notably, the KEGG pathway (complement and coagulation cascade) is enriched, and three key activators were up-regulated: von willebrand factor (VWF), coagulation factor v (F5) and vitamin k-dependent protein c (PC). Protein-protein interaction (PPI) analysis showed that six proteins ((VWF, F5, thrombin reactive protein 1 (THBS1), mannose-binding lectin-associated serine protease 2 (MASP2), apolipoprotein B (APOB), and apolipoprotein (a) (LPA)) were up-regulated and two proteins (Metalloproteinase inhibitor 1(TIMP1), ferritin light chain (FTL)) were down-regulated. The results of this study showed that several proteins involved in complement and coagulation cascades were up-regulated in the serum of patients.
Collapse
Affiliation(s)
- Jiaduo Li
- People's Hospital of Shijiazhuang Affiliated to Hebei Medical University, Shijiazhuang, Hebei, China
| | - Guoyan Qi
- People's Hospital of Shijiazhuang Affiliated to Hebei Medical University, Shijiazhuang, Hebei, China.
| | - Yaling Liu
- People's Hospital of Shijiazhuang Affiliated to Hebei Medical University, Shijiazhuang, Hebei, China
| |
Collapse
|
5
|
Yang H, Qi G, Dong H, Liu Z, Ma M, Liu P. Identification of Potential Serum Protein Biomarkers in Thymoma with Myasthenia Gravis After Docetaxel Treatment. Neurol Ther 2023; 12:559-570. [PMID: 36786935 PMCID: PMC10043105 DOI: 10.1007/s40120-023-00442-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2022] [Accepted: 01/23/2023] [Indexed: 02/15/2023] Open
Abstract
INTRODUCTION Myasthenia gravis (MG) is a devastating acquired autoimmune disease that can seriously affect the patient's quality of life. It is also a common complication of thymoma. Previous studies have shown that docetaxel alleviates myasthenic symptoms in thymoma with MG (TMG). However, little is known about the protein expression profiles and biomarkers for efficacy after docetaxel treatment. METHODS We recruited 9 healthy controls and 30 patients with TMG for the serum proteomics study with data-independent acquisition (DIA) technology. We further recruited additional 30 patients for the key protein validation by enzyme-linked immunosorbent assay (ELISA). RESULTS We identified 43 proteins by trend analysis and analyzed the interaction between these proteins and MG pathogenic proteins from the DisGNET database and the correlation analysis with clinical data of patients with TMG. Among these, KRAS and SELP were screened out and validated. KRAS and SELP increased in patients with TMG and decreased significantly after docetaxel treatment. CONCLUSIONS Our study revealed that the serum proteins were differentially expressed after docetaxel treatment, suggesting their important role in patients with TMG, as well as the critical role of KRAS and SELP as biomarkers in evaluating the efficacy of docetaxel treatment.
Collapse
Affiliation(s)
- Hongxia Yang
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang Affiliated to Hebei Medical University, 365 Jianhua Nan Street, Shijiazhuang, Hebei, China.,Hebei Provincial Clinical Research Center for Myasthenia Gravis, Shijiazhuang, China
| | - Guoyan Qi
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang Affiliated to Hebei Medical University, 365 Jianhua Nan Street, Shijiazhuang, Hebei, China. .,Hebei Provincial Key Laboratory of Myasthenia Gravis, Shijiazhuang, China. .,Hebei Provincial Clinical Research Center for Myasthenia Gravis, Shijiazhuang, China.
| | - Huimin Dong
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang Affiliated to Hebei Medical University, 365 Jianhua Nan Street, Shijiazhuang, Hebei, China
| | - Ze Liu
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang Affiliated to Hebei Medical University, 365 Jianhua Nan Street, Shijiazhuang, Hebei, China.,Hebei Provincial Key Laboratory of Myasthenia Gravis, Shijiazhuang, China
| | - Mei Ma
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang Affiliated to Hebei Medical University, 365 Jianhua Nan Street, Shijiazhuang, Hebei, China
| | - Peng Liu
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang Affiliated to Hebei Medical University, 365 Jianhua Nan Street, Shijiazhuang, Hebei, China.,Hebei Provincial Key Laboratory of Myasthenia Gravis, Shijiazhuang, China
| |
Collapse
|
6
|
Li J, Qi G, Liu Y. Anxiety and depression in thymoma patients in China before surgery. J Cardiothorac Surg 2022; 17:313. [PMID: 36527139 PMCID: PMC9756615 DOI: 10.1186/s13019-022-02081-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Accepted: 12/10/2022] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND The study's goal was to investigate the percentage of anxiety and depression in Chinese thymoma patients before surgery, and also the factors that influence it. METHODS The study included patients who had an anterior mediastinal mass discovered by chest CT and were scheduled for video-assisted thoracoscopic surgery. The mental health rating scales were completed by all patients before surgery. Patients were divided into two groups based on the Hospital Anxiety and Depression Scale (HADS): anxiety/depression and non-anxiety/depression. The association between thymoma clinical factors and the HADS score was studied statistically. RESULTS The study comprised eighty patients with thymoma. Before the operation, 22.5% (18/80) of the patients had anxiety and/or depression. The resigned coping style characteristics, along with myasthenia gravis (MG), were associated with preoperative anxiety and depression. The greater the score of the resigned dimension, the greater the risk of anxiety and depression, based on the results of logical regression analysis. Thymoma patients with myasthenia gravis have a higher risk of anxiety and depression. CONCLUSION Patients with myasthenia gravis and resigned coping style were found to have higher anxiety and depression before surgery for Chinese thymoma patients.
Collapse
Affiliation(s)
- Jiaduo Li
- grid.256883.20000 0004 1760 8442Center of Treatment of Myasthenia Gravis, People’s Hospital of Shijiazhuang Affiliated to Hebei Medical University, Shijiazhuang, Hebei Province China
| | - Guoyan Qi
- grid.256883.20000 0004 1760 8442Center of Treatment of Myasthenia Gravis, People’s Hospital of Shijiazhuang Affiliated to Hebei Medical University, Shijiazhuang, Hebei Province China
| | - Yaling Liu
- grid.256883.20000 0004 1760 8442Center of Treatment of Myasthenia Gravis, People’s Hospital of Shijiazhuang Affiliated to Hebei Medical University, Shijiazhuang, Hebei Province China
| |
Collapse
|
7
|
Liu P, Qi G, Gu S, Dong H, Liu C, Yang H. Single-cell transcriptomics and network pharmacology reveal therapeutic targets of Jianpi Yiqi Bugan Yishen decoction in immune cell subsets of children with myasthenia gravis. Transl Pediatr 2022; 11:1985-2003. [PMID: 36643680 PMCID: PMC9834954 DOI: 10.21037/tp-22-593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2022] [Accepted: 12/05/2022] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Myasthenia gravis (MG) is an acquired autoimmune disease of the neuromuscular junction. As immunosuppressive agents used to treat MG have a significant impact on the growth and development of children, treatment is extremely challenging. Jianpi Yiqi Bugan Yishen Decoction (JYBYD) has been developed to treat MG and has achieved satisfactory results in clinical practice. This study aimed to explore its action mechanism and evaluate its active ingredients and potential therapeutic targets. METHODS Single-cell transcriptome sequencing of peripheral blood immune cells of children with MG was performed to reveal the changes in immune cell profiles before and after JYBYD treatment. Lewis rats were included in the model, with classic MG induced by subcutaneous injection of the immunogen acetylcholine receptor (AChR). Twenty rats were divided into two groups and administered normal saline and JYBYD by gavage daily. RESULTS An increase in cell populations characterized by cortactin expression was observed, which has a potential effect on the recovery of lesions at the neuromuscular junction in patients with MG. Based on the differential expression of genes in various immune cells and the predicted targets of traditional Chinese medicine (TCM) compounds, the possible therapeutic targets of JYBYD in different cell subsets were identified, among which STAT1, MCL1, and FOS were the most frequent. Comprehensive network pharmacological analysis suggested quercetin, luteolin, and resveratrol as important active ingredients of JYBYD for the treatment of children with MG. JYBYD could relieve myasthenia symptoms and reduce the AChR-Ab titer in the rat model. Immunohistochemistry results of the muscle showed that JYBYD treatment decreased the expression of STAT1, MCL1, and c-FOS proteins in the muscles of MG rat models. CONCLUSIONS The results of this study are of significance for the clinical application of JYBYD and drug development against MG in children.
Collapse
Affiliation(s)
- Peng Liu
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang Affiliated to Hebei Medical University, Shijiazhuang, China.,Hebei Provincial Key Laboratory of Myasthenia Gravis, Shijiazhuang, China
| | - Guoyan Qi
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang Affiliated to Hebei Medical University, Shijiazhuang, China.,Hebei Provincial Key Laboratory of Myasthenia Gravis, Shijiazhuang, China.,Hebei Provincial Clinical Research Center for Myasthenia Gravis, Shijiazhuang, China
| | - Shanshan Gu
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang Affiliated to Hebei Medical University, Shijiazhuang, China.,Hebei Provincial Clinical Research Center for Myasthenia Gravis, Shijiazhuang, China
| | - Huimin Dong
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang Affiliated to Hebei Medical University, Shijiazhuang, China
| | - Chaoying Liu
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang Affiliated to Hebei Medical University, Shijiazhuang, China.,Hebei Provincial Key Laboratory of Myasthenia Gravis, Shijiazhuang, China
| | - Hongxia Yang
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang Affiliated to Hebei Medical University, Shijiazhuang, China
| |
Collapse
|
8
|
Cheng B, Xue Y, Gu S, Yang H, Liu P, Qi G. Developing and validating a nomogram to predict myasthenia gravis exacerbation in patients with postoperative thymoma recurrence. Gland Surg 2022; 11:1712-1721. [DOI: 10.21037/gs-22-549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Accepted: 10/14/2022] [Indexed: 11/04/2022]
|
9
|
Li J, Liu Y, Zhang X, Zheng X, Qi G. Prognostic factors for overall survival after surgical resection in patients with thymic epithelial tumors: A systematic review and meta-analysis. Medicine (Baltimore) 2022; 101:e30867. [PMID: 36181069 PMCID: PMC9524934 DOI: 10.1097/md.0000000000030867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Thymic epithelial tumors (TETs) originate in the thymic epithelial cell, including thymoma and thymic carcinoma. Surgical resection is the first choice for most patients. However, some studies have shown that the factors affecting the prognosis of these patients are not consistent. To evaluate prognostic factors in patients with surgically resected thymic epithelial tumors, we performed a meta-analysis. METHODS We searched the Chinese biomedical literature database, Pubmed, Embase, Cochrane Library and other electronic databases. Studies including postoperative overall survival (OS) and predictors of TETs were included. We made a comprehensive analysis the hazard ratios (HRs) through a single proportional combination. HRs were combined using single proportion combinations. RESULTS The meta-analysis included 11,695 patients from 26 studies. The pooled OS was 84% at 5 years and 73% at 10 years after TETs operation. The age as continuous-year (HR 1.04, 95% confidence interval (CI) 1.02-1.04), incomplete resection (HR 4.41, 95% CI 3.32-5.85), WHO histologic classification (B2/B3 vs A/AB/B1 HR 2.76, 95% CI 1.25-6.21), Masaoka Stage (stage III/IV vs I/II HR 2.74, 95% CI 2.12-3.55,) were the poor prognostic factors. CONCLUSIONS For patients with TETs after surgical resection, advanced age, incomplete resection, WHO classification B2/B3, and higher Masaoka stage are risk factors for poor prognosis.
Collapse
Affiliation(s)
- Jiaduo Li
- People’s Hospital of Shijiazhuang affiliated to Hebei Medical University - Center of Treatment of Myasthenia Gravis, Shijiazhuang, Hebei, China
| | - Yaling Liu
- People’s Hospital of Shijiazhuang affiliated to Hebei Medical University - Center of Treatment of Myasthenia Gravis, Shijiazhuang, Hebei, China
| | - Xiaohe Zhang
- People’s Hospital of Shijiazhuang affiliated to Hebei Medical University - Center of Treatment of Myasthenia Gravis, Shijiazhuang, Hebei, China
| | - Xuguang Zheng
- People’s Hospital of Shijiazhuang affiliated to Hebei Medical University - Center of Treatment of Myasthenia Gravis, Shijiazhuang, Hebei, China
| | - Guoyan Qi
- People’s Hospital of Shijiazhuang affiliated to Hebei Medical University - Center of Treatment of Myasthenia Gravis, Shijiazhuang, Hebei, China
- *Correspondence: Guoyan Qi, People’s Hospital of Shijiazhuang affiliated to Hebei Medical University, Center of Treatment of Myasthenia Gravis, Shijiazhuang, Hebei, 050011, China (e-mail: )
| |
Collapse
|
10
|
Lin X, Qi G. Observation on the efficacy of different methylprednisolone regimens in the treatment of myasthenia gravis. Pak J Med Sci 2022; 38:910-915. [PMID: 35634618 PMCID: PMC9121932 DOI: 10.12669/pjms.38.4.5069] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2021] [Revised: 08/20/2021] [Accepted: 12/29/2021] [Indexed: 11/15/2022] Open
Abstract
Objective: To investigate the efficacy of different methylprednisolone regimens in the treatment of myasthenia gravis (MG). Methods: A total of 98 patients with MG admitted to Shijiazhuang People’s Hospital from December 2018 to November 2019 were randomly divided into two groups, with 49 cases in each group. Patients in the control group received high-dose methylprednisolone pulse therapy, while those in the experimental group received medium-dose periodic therapy of methylprednisolone. Anti-acetylcholine receptor antibodies (AChRab), clinical absolute scores, complement levels (C3, C4), T lymphocyte subsets (CD3+, CD4+, CD4+CD25+), cytokines [interferon-γ (INF-γ), transforming growth factor-β1 (TGF-β1), interleukin-6 (IL- 6), interleukin-18 (IL-18)], and changes in quality of life [15-item Myasthenia Gravis Quality of Life Scale (MGQOL-15) score] were compared between the two groups before treatment and one and three months after treatment. Moreover, the incidence of adverse drug reactions in the two groups during 3 months of treatment was compared. Results: After three months of treatment, ACHRAB, clinical absolute score, CD3+, CD4+, INF-γ, IL-6, IL-18 and MGQOL-15 scores in both groups were significantly decreased compared with those before treatment (p<0.05), and the scores of C3, C4, CD4+CD25+ and TGF-β1 in both groups were significantly higher than those before treatment (p<0.05), and the experimental group had more significant changes than the control group (p<0.05). During three months of treatment, the total incidence of adverse drug reactions in the experimental group was significantly lower than that in the control group (p<0.05). Conclusions: The medium-dose periodic therapy of methylprednisolone is more prominent in the long-term efficacy performance. It can improve the immunity and quality of life of patients, and it is safer and has high clinical application value.
Collapse
Affiliation(s)
- Xiaoting Lin
- Xiaoting Lin, Center of Treatment of Myasthenia Gravis Hebei Province, Shijiazhuang People’s Hospital, Shijiazhuang, 050000, Hebei, China
- Correspondence: Xiaoting Lin, Center of Treatment of Myasthenia Gravis Hebei Province, Shijiazhuang People’s Hospital, Shijiazhuang, 050000, Hebei, China.
| | - Guoyan Qi
- Guoyan Qi, Center of Treatment of Myasthenia Gravis Hebei Province, Shijiazhuang People’s Hospital, Shijiazhuang, 050000, Hebei, China
| |
Collapse
|
11
|
Wang Y, Qi G, Yang Y. Analysis of clinical features of myasthenia gravis complicated with hyperthyroidism. Pak J Med Sci 2022; 38:530-535. [PMID: 35480500 PMCID: PMC9002454 DOI: 10.12669/pjms.38.3.4656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Revised: 11/15/2021] [Accepted: 11/28/2021] [Indexed: 11/15/2022] Open
Abstract
Objectives: To investigate the clinical features of patients with myasthenia gravis complicated with and without hyperthyroidism. Methods: A total of 2083 patients with myasthenia gravis (MG) admitted in Center of Treatment of Myasthenia Gravis Hebei Province between January 2013 and July 2020 were retrospectively analyzed and divided into two groups: Group-A and Group-B, with 108 MG patients complicated with hyperthyroidism in Group-A and 1975 MG patients without thyroid disease in Group-B. The age of onset, gender, Osserman classification, acetylcholine receptor antibody and thymus status of the two groups were analyzed in the two groups. Independent-sample t test was used for intra-group comparison, and χ2 test was utilized for comparison of enumeration data. P<0.05 indicates a statistically significant difference. Results: The age of onset in Group-A was significantly lower than that in Group-B (p=0.000), the number of female patients was significantly higher than that in Group-B (p=0.037), and the level of Achrabs titer was significantly lower than that in Group-B (p=0.000). The incidence of thymoma in Group-A was significantly lower than that in Group-B (p=0.012), while the incidence of thymic hyperplasia was significantly higher than that in Group-B (p=0.000). Conclusion: Patients with MG complicated with hyperthyroidism are mainly female, with a lower age of onset, a lower level of acetylcholine receptor antibody, a lower incidence of thymoma, and a higher incidence of thymic hyperplasia. The clinical features of such patients are remarkably different from those of MG without thyroid disease.
Collapse
Affiliation(s)
- Yaxuan Wang
- Yaxuan Wang, Center of Treatment of Myasthenia Gravis Hebei Province, Shi Jiazhuang People’s Hospital, Shi Jiazhuang, 050000, Hebei, China
- Correspondence: Yaxuan Wang, Center of Treatment of Myasthenia Gravis Hebei Province, Shi Jiazhuang People’s Hospital, Shi Jiazhuang, 050000, Hebei, China E-mail:
| | - Guoyan Qi
- Guoyan Qi, Center of Treatment of Myasthenia Gravis Hebei Province, Shi Jiazhuang People’s Hospital, Shi Jiazhuang, 050000, Hebei, China
| | - Ying Yang
- Ying Yang, Center of Treatment of Myasthenia Gravis Hebei Province, Shi Jiazhuang People’s Hospital, Shi Jiazhuang, 050000, Hebei, China
| |
Collapse
|
12
|
Li J, Qi G, Liu Y. Effect of Buzhong Yiqi decoction on anti-acetylcholine receptor antibody and clinical status in juvenile ocular myasthenia gravis. Medicine (Baltimore) 2021; 100:e27688. [PMID: 34871253 PMCID: PMC8568406 DOI: 10.1097/md.0000000000027688] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/24/2020] [Accepted: 10/18/2021] [Indexed: 01/21/2023] Open
Abstract
Ocular myasthenia gravis (MG) is the mainly widespread type of MG among juveniles. Buzhong Yiqi decoction (BZ) is a well-known traditional Chinese medicine prescription for treating MG. It has rarely been discussed whether the concentration of anti-acetylcholine receptor (AChR) antibodies is related to the clinical status of juvenile ocular myasthenia gravis (JOMG) treated with BZ.The patients with JOMG who had more than once AChR-antibody (ab) test and treated with BZ were retrospectively identified from June 2013 to January 2020 in the first hospital in Shijiazhuang. The presence or absence of ocular symptoms was used to grade the effectiveness of treatment. Generalized estimating equations logistic regression analysis was used to evaluate the effect of AChR ab concentration on the clinical status of MG.A total of 549 AChR-ab tests were performed in 135 patients, and the corresponding clinical status was recorded. One hundred two patients received treatment with BZ only and 33 combined with immunosuppressive drugs. In the group receiving only BZ treatment, the anti-acetylcholine receptor ab concentration was positively correlated with the clinical score after treatment.The results suggest that BZ could affect the AChR-ab. Repeated AChR-ab assays can provide information about the clinical status. For JOMG patients who only receive Buzhong Yiqi Decoction treatment, this can support treatment decisions.
Collapse
Affiliation(s)
- Jiaduo Li
- Center of Treatment of Myasthenia Gravis, People‘s Hospital of Shijiazhuang Affiliated to Hebei Medical University, China
| | - Guoyan Qi
- Center of Treatment of Myasthenia Gravis, People‘s Hospital of Shijiazhuang Affiliated to Hebei Medical University, China
| | - Yaling Liu
- Gastroenterology Department, People‘s Hospital of Shijiazhuang Affiliated to Hebei Medical University, China
| |
Collapse
|
13
|
Liu P, Jiang Y, Gu S, Xue Y, Yang H, Li Y, Wang Y, Yan C, Jia P, Lin X, Qi G. Metagenome-wide association study of gut microbiome revealed potential microbial marker set for diagnosis of pediatric myasthenia gravis. BMC Med 2021; 19:159. [PMID: 34233671 PMCID: PMC8265136 DOI: 10.1186/s12916-021-02034-0] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Accepted: 06/11/2021] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND Myasthenia gravis (MG) is an acquired immune-mediated disorder of the neuromuscular junction that causes fluctuating skeletal muscle weakness and fatigue. Pediatric MG and adult MG have many different characteristics, and current MG diagnostic methods for children are not quite fit. Previous studies indicate that alterations in the gut microbiota may be associated with adult MG. However, it has not been determined whether the gut microbiota are altered in pediatric MG patients. METHODS Our study recruited 53 pediatric MG patients and 46 age- and gender-matched healthy controls (HC). We sequenced the fecal samples of recruited individuals using whole-genome shotgun sequencing and analyzed the data with in-house bioinformatics pipeline. RESULTS We built an MG disease classifier based on the abundance of five species, Fusobacterium mortiferum, Prevotella stercorea, Prevotella copri, Megamonas funiformis, and Megamonas hypermegale. The classifier obtained 94% area under the curve (AUC) in cross-validation and 84% AUC in the independent validation cohort. Gut microbiome analysis revealed the presence of human adenovirus F/D in 10 MG patients. Significantly different pathways and gene families between MG patients and HC belonged to P. copri, Clostridium bartlettii, and Bacteroides massiliensis. Based on functional annotation, we found that the gut microbiome affects the production of short-chain fatty acids (SCFAs), and we confirmed the decrease in SCFA levels in pediatric MG patients via serum tests. CONCLUSIONS The study indicated that altered fecal microbiota might play vital roles in pediatric MG's pathogenesis by reducing SCFAs. The microbial markers might serve as novel diagnostic methods for pediatric MG.
Collapse
Affiliation(s)
- Peng Liu
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang affiliated to Hebei Medical University, Shijiazhuang, China.,Hebei Provincial Key Laboratory of Myasthenia Gravis, Shijiazhuang, China
| | - Yiqi Jiang
- City University of Hong Kong, Hong Kong, China
| | - Shanshan Gu
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang affiliated to Hebei Medical University, Shijiazhuang, China.,Hebei Provincial Clinical Research Center for Myasthenia gravis, Shijiazhuang, China
| | - Yinping Xue
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang affiliated to Hebei Medical University, Shijiazhuang, China.,Hebei Provincial Clinical Research Center for Myasthenia gravis, Shijiazhuang, China
| | - Hongxia Yang
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang affiliated to Hebei Medical University, Shijiazhuang, China.,Hebei Provincial Clinical Research Center for Myasthenia gravis, Shijiazhuang, China
| | - Yongzhao Li
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang affiliated to Hebei Medical University, Shijiazhuang, China.,Hebei Provincial Clinical Research Center for Myasthenia gravis, Shijiazhuang, China
| | - Yaxuan Wang
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang affiliated to Hebei Medical University, Shijiazhuang, China
| | - Congya Yan
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang affiliated to Hebei Medical University, Shijiazhuang, China
| | - Pei Jia
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang affiliated to Hebei Medical University, Shijiazhuang, China
| | - Xiaoting Lin
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang affiliated to Hebei Medical University, Shijiazhuang, China
| | - Guoyan Qi
- Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang affiliated to Hebei Medical University, Shijiazhuang, China. .,Hebei Provincial Key Laboratory of Myasthenia Gravis, Shijiazhuang, China. .,Hebei Provincial Clinical Research Center for Myasthenia gravis, Shijiazhuang, China.
| |
Collapse
|
14
|
Liu C, Liu P, Ma M, Yang H, Qi G. Efficacy and safety of double-filtration plasmapheresis treatment of myasthenia gravis: A systematic review and meta-analysis. Medicine (Baltimore) 2021; 100:e25622. [PMID: 33907116 PMCID: PMC8084046 DOI: 10.1097/md.0000000000025622] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/09/2020] [Revised: 12/09/2020] [Accepted: 04/03/2021] [Indexed: 11/25/2022] Open
Abstract
OBJECTIVES To evaluate the efficacy of double-filtration plasmapheresis (DFPP) treatment of myasthenia gravis (MG) through a systematic review and meta-analysis. METHODS PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), and Wanfang databases were searched for randomized controlled trials (RCTs) and clinical controlled trials (CCTs) on DFPP for MG from database establishment to June 2019. Two researchers independently screened the articles, extracted the data, and cross checked the results. RevMan 5.3 was used for statistical analyses. RESULTS Seven RCTs and 2 CCTs were found comprising 329 patients. The results showed that clinical MG remission rate after DFPP treatment was significantly higher (OR = 4.33; 95% confidence interval [CI], 1.97-9.53; P < .001) and the serum levels of antititin antibody was significantly decreased (standardized mean difference [SMD] = 9.30; 95% CI, 7.51-11.08; P < .001). In addition, the quantitative MG (QMG) score, hospital stay and time to remission of MG symptoms, and acetylcholine receptor antibody (AchRAb) decreased in the DFPP treatment group; however, these outcomes had high heterogeneity among the studies. Only one study has reported on the adverse effects, including hypotension and hematoma. CONCLUSION This meta-analysis suggests that DFPP can be recommended for the short-term mitigation of MG. Because our review was limited by the quantity and quality of the included studies, the above conclusions should be verified by additional high-quality studies.
Collapse
|
15
|
Liu C, Liu P, Zhang XJ, Li WQ, Qi G. Assessment of the risks of a myasthenic crisis after thymectomy in patients with myasthenia gravis: a systematic review and meta-analysis of 25 studies. J Cardiothorac Surg 2020; 15:270. [PMID: 32993739 PMCID: PMC7526111 DOI: 10.1186/s13019-020-01320-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2020] [Accepted: 09/21/2020] [Indexed: 01/11/2023] Open
Abstract
Background Despite the burgeoning literature describing preoperative and postoperative risks of a myasthenic crisis after thymectomy (MCAT) in patients with myasthenia gravis, substantial differences exist in the risk factors identified by previous studies. We conducted a meta-analysis to assess the reported risk factors and MCAT risk. Methods We collected relevant studies on the risk factors for MCAT by searching the PubMed, Embase, The Cochrane Library, China Biology Medicine (CBM), WanFang Data, VIP and CNKI databases. The search period ranged from the establishment of the database to November 2019. Results Twenty-five of the 458 identified studies were eligible for the meta-analysis. Seven retrospective cohort studies and 18 case-control studies were included, and 14 risk factors for MCAT were extracted. Meta-analyses of the association between MCAT and risk factors related to the patient’s preoperative condition included a preoperative history of MC, preoperative bulbar symptoms, IIa + IIb + III + VI, IIb + III + VI, VI + V, dosage of pyridostigmine bromide prior to the operation, a preoperative AchR-Ab level > 100 (nm/L), preoperative pulmonary function, preoperative complications, and preoperative disease course. Meta-analyses of the association between MCAT and surgery-related risk factors included intraoperative blood loss > 1000 mL and the mode of operation. Meta-analyses of the association between MCAT and postoperative risk factors included postoperative lung infection, thymoma and the WHO classification. The operation time was not an independent risk factor for MCAT. Conclusions The independent risk factors for MCAT were a preoperative history of MC, preoperative bulbar symptoms, preoperative MG Osserman stage, preoperative dosage of pyridostigmine bromide, preoperative serum AchR-Ab level, lung function, major postoperative complications, disease duration before thymectomy, blood loss, thoracotomy, postoperative lung infection, thymoma, and WHO classification.
Collapse
Affiliation(s)
- Chaoying Liu
- Hebei Key Laboratory of Myasthenia Gravis, Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, No. 9 Fangbei Road, Chang'an District, Shijiazhuang, 050011, Hebei Province, China
| | - Peng Liu
- Hebei Key Laboratory of Myasthenia Gravis, Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, No. 9 Fangbei Road, Chang'an District, Shijiazhuang, 050011, Hebei Province, China
| | - Xiao Jing Zhang
- Hebei Key Laboratory of Myasthenia Gravis, Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, No. 9 Fangbei Road, Chang'an District, Shijiazhuang, 050011, Hebei Province, China
| | - Wen Qian Li
- Hebei Key Laboratory of Myasthenia Gravis, Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, No. 9 Fangbei Road, Chang'an District, Shijiazhuang, 050011, Hebei Province, China
| | - Guoyan Qi
- Hebei Key Laboratory of Myasthenia Gravis, Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, No. 9 Fangbei Road, Chang'an District, Shijiazhuang, 050011, Hebei Province, China.
| |
Collapse
|
16
|
Lu W, Qi G, Ding Z, Li X, Qi W, He F. Clinical efficacy of acellular dermal matrix for plastic periodontal and implant surgery: a systematic review. Int J Oral Maxillofac Surg 2020; 49:1057-1066. [DOI: 10.1016/j.ijom.2019.12.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Revised: 12/02/2019] [Accepted: 12/12/2019] [Indexed: 11/24/2022]
|
17
|
Li J, Qi G, Liu Y, Zheng X, Zhang X. Meta-analysis of subxiphoid approach versus lateral approach for thoracoscopic Thymectomy. J Cardiothorac Surg 2020; 15:89. [PMID: 32398115 PMCID: PMC7216611 DOI: 10.1186/s13019-020-01135-w] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2019] [Accepted: 05/04/2020] [Indexed: 11/22/2022] Open
Abstract
Background Compared with traditional open surgery for thymectomy, video-assisted thoracoscopic surgery (VATS) reduces hospital stay, decreases postoperative pain, and recovers faster. VATS has become increasingly popular in the past decade. VATS techniques to perform a thymectomy include subxiphoid video-assisted thoracoscopic surgery (SVATS) or lateral video-assisted thoracoscopic surgery (LVATS). In this study, our objective was to systematically review on VATS thymectomy and draw a meta-analysis on the outcomes between the two approaches. Methods We searched online databases and identified studies from database inception to 2019 that compared SVATS to LVATS thymectomy. Study endpoints included operative time, operative blood loss, length of hospital stay, postoperative pleural drainage, postoperative complications, conversion to open, oncologic outcomes. Results Four hundred seventy-one patients were included in this study, for which 200 and 271 patients underwent SVATS and LVATS thymectomy, respectively. Patients in the SVATS group had significantly less operative time, operative blood loss, length of hospital stay, and postoperative complications were identified. There was no statistical difference in postoperative pleural drainage, conversion to open and oncologic outcomes. No hospital deaths were recorded for either procedure. Conclusions While randomized controlled studies are required to make definitive conclusions, this meta-analysis suggests that SVATS thymectomy is safe and can achieve good and safe operative and perioperative outcomes similar or better to LVATS thymectomy.
Collapse
Affiliation(s)
- Jiaduo Li
- Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, Fangbei road No. 9, Shijiazhuang, 050011, Hebei Province, China
| | - Guoyan Qi
- Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, Fangbei road No. 9, Shijiazhuang, 050011, Hebei Province, China.
| | - Yaling Liu
- Department of Gastroenterology, First Hospital of Shijiazhuang, Shijiazhuang, China
| | - Xuguang Zheng
- Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, Fangbei road No. 9, Shijiazhuang, 050011, Hebei Province, China
| | - Xiaohe Zhang
- Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, Fangbei road No. 9, Shijiazhuang, 050011, Hebei Province, China
| |
Collapse
|
18
|
Li J, Qi G, Zhang X, Zheng X. Is chest tube drainage necessary after subxiphoid thoracoscopic thymectomy? J Cardiothorac Surg 2020; 15:66. [PMID: 32321552 PMCID: PMC7178578 DOI: 10.1186/s13019-020-01102-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2019] [Accepted: 04/06/2020] [Indexed: 11/22/2022] Open
Abstract
Background Subxiphoid thoracoscopic thymectomy has been increasingly performed in recent years. This study aimed to assess the differences in outcomes between subxiphoid thoracoscopic thymectomy with and without chest tube drainage. Methods Overall, 205 subxiphoid thoracoscopic thymectomy operations were performed for myasthenia gravis, including 90 cases without and 115 cases with chest tube drainage. The clinical characteristics and perioperative outcomes of the patients were compared. Results The patients included 112 women and 93 men, with a mean age of 41 years. Two patients in the group without and 5 patient in the group with chest tube drainage developed dyspnea. In the group without chest tube, 6 patients had residual pneumothorax or pleural effusion and had a thoracentesis after surgery (6/90). In the group with chest tube, 7 patients developed delayed pleural effusion and had a thoracentesis after chest tube removal (7/115). The patients in the group without chest tube drainage group yielded lower pain scores. Conclusions The omission of chest tube drainage may be a feasible and safe choice for patients with myasthenia gravis undergoing subxiphoid thoracoscopic thymectomy, but further prospective studies are required.
Collapse
Affiliation(s)
- Jiaduo Li
- Center of Treatment of Myasthenia Gravis Hebei Province, People's Hospital affiliated to Hebei Medical University, Fangbei road No. 9, Shijiazhuang, 050011, Hebei Province, China
| | - Guoyan Qi
- Center of Treatment of Myasthenia Gravis Hebei Province, People's Hospital affiliated to Hebei Medical University, Fangbei road No. 9, Shijiazhuang, 050011, Hebei Province, China. .,Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, Fangbei road No. 9, Shijiazhuang, 050011, Hebei Province, China.
| | - Xiaohe Zhang
- Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, Fangbei road No. 9, Shijiazhuang, 050011, Hebei Province, China
| | - Xuguang Zheng
- Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, Fangbei road No. 9, Shijiazhuang, 050011, Hebei Province, China
| |
Collapse
|
19
|
Wang H, Qi G, Zhang H, Wang X, Wu S, Wang J, Yue H. 177 Effect of dietary choline and Schizochytrium oil on DHA content in the egg yolk and egg quality during storage. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- H Wang
- Feed Research Institute of Chinese Academy of Agricultural Sciences,Beijing, China
| | - G Qi
- Feed Research Institute of Chinese Academy of Agricultural Sciences,Beijing, China
| | - H Zhang
- Feed Research Institute of Chinese Academy of Agricultural Sciences,Beijing, China
| | - X Wang
- Feed Research Institute of Chinese Academy of Agricultural Sciences,Beijing, China
| | - S Wu
- Feed Research Institute of Chinese Academy of Agricultural Sciences,Beijing, China
| | - J Wang
- Feed Research Institute of Chinese Academy of Agricultural Sciences,Beijing, China
| | - H Yue
- Feed Research Institute of Chinese Academy of Agricultural Sciences,Beijing, China
| |
Collapse
|
20
|
Hu M, Qi G, Wang J, Wu S, Yu H. 188 Effects of dietary supplementation of L-histidine and beta-alanine on growth performance, breast muscle carnosine content and carnosine-related enzyme mRNA expression in broiler chicks. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.666] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M Hu
- Feed Research Institute of Chinese Academy of Agricultural Sciences,Beijing, China
| | - G Qi
- Feed Research Institute of Chinese Academy of Agricultural Sciences,Beijing, China
| | - J Wang
- Feed Research Institute of Chinese Academy of Agricultural Sciences,Beijing, China
| | - S Wu
- Feed Research Institute of Chinese Academy of Agricultural Sciences,Beijing, China
| | - H Yu
- Feed Research Institute of Chinese Academy of Agricultural Sciences,Beijing, China
| |
Collapse
|
21
|
Qi G, Liu P, Gu S, Yang H, Dong H, Xue Y. Whole-exome sequencing reveals a rare interferon gamma receptor 1 mutation associated with myasthenia gravis. Neurol Sci 2018; 39:717-724. [PMID: 29441481 DOI: 10.1007/s10072-018-3275-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2017] [Accepted: 02/02/2018] [Indexed: 10/18/2022]
Abstract
Our study is aimed to explore the underlying genetic basis of myasthenia gravis. We collected a Chinese pedigree with myasthenia gravis, and whole-exome sequencing was performed on the two affected siblings and their parents. The candidate pathogenic gene was identified by bioinformatics filtering, which was further verified by Sanger sequencing. The homozygous mutation c.G40A (p.V14M) in interferon gamma receptor 1was identified. Moreover, the mutation was also detected in 3 cases of 44 sporadic myasthenia gravis patients. The p.V14M substitution in interferon gamma receptor 1 may affect the signal peptide function and the translocation on cell membrane, which could disrupt the binding of the ligand of interferon gamma and antibody production, contributing to myasthenia gravis susceptibility. We discovered that a rare variant c.G40A in interferon gamma receptor 1 potentially contributes to the myasthenia gravis pathogenesis. Further functional studies are needed to confirm the effect of the interferon gamma receptor 1 on the myasthenia gravis phenotype.
Collapse
Affiliation(s)
- Guoyan Qi
- Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, Fangbei road No. 9, Shijiazhuang, Hebei Province, 050011, China.
| | - Peng Liu
- Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, Fangbei road No. 9, Shijiazhuang, Hebei Province, 050011, China
| | - Shanshan Gu
- Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, Fangbei road No. 9, Shijiazhuang, Hebei Province, 050011, China
| | - Hongxia Yang
- Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, Fangbei road No. 9, Shijiazhuang, Hebei Province, 050011, China
| | - Huimin Dong
- Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, Fangbei road No. 9, Shijiazhuang, Hebei Province, 050011, China
| | - Yinping Xue
- Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, Fangbei road No. 9, Shijiazhuang, Hebei Province, 050011, China
| |
Collapse
|
22
|
Qi G, Xue Y, Li Y, Yang H, Zhang X. Docetaxel/cisplatin Therapy in Myasthenia Gravis with Hypertension/diabetes. Open Med (Wars) 2017; 12:403-408. [PMID: 29318185 PMCID: PMC5757353 DOI: 10.1515/med-2017-0058] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2017] [Accepted: 10/20/2017] [Indexed: 02/07/2023] Open
Abstract
Background Therapeutic options for thymoma-associated myasthenia gravis (MG) patients complicated with hypertension and/or diabetes post thymectomy are often conventional steroids. As the prevalence of diabetes and hypertension globally increases, other therapeutic options for these patients are of great importance. Material/methods 9 patients with thymoma-associated MG complicated with hypertension and/or diabetes after thymectomy were administered 75 mg/m2 of docetaxel and 70 mg/m2 of cisplatin on day 1. The treatment could be repeated at 3-week intervals, ranging from 1 to 4 cycles according to the status of the patients. Therapeutic efficacy and side effects were evaluated. Results 2 patients were complicated with type 2 diabetes, 6 with hypertension, and 1 with both diabetes and hypertension. After docetaxel/cisplain therapy, the MG symptoms were markedly improved in all patients (2, complete remission; 3, basic remission; 3, marked improvement; 1, improvement). Acetylcholine receptor (AchR) antibody levels were decreased in 8 patients. Minor adverse effects were observed in 2 patients, 1 with Grade II gastrointestinal reaction, and the other with pulmonary infection. Conclusion Docetaxel plus cisplatin might be an effective therapeutic option for thymoma-associated MG patients complicated with hypertension /diabetes post thymectomy without worsening thymoma and hypertension / diabetes.
Collapse
Affiliation(s)
- Guoyan Qi
- No. 9 Fangbei Road, Chang'an District, Shijiangzhuang 050011, Hebei Province, China
| | - Yinping Xue
- Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, Shijiazhuang050011, China
| | - Yongzhao Li
- Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, Shijiazhuang050011, China
| | - Hongxia Yang
- Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, Shijiazhuang050011, China
| | - Xiaojing Zhang
- Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, Shijiazhuang050011, China
| |
Collapse
|
23
|
Qi G, Liu P, Gu S, Yang H, Dong H, Xue Y. Effect of Jianpiyiqi granule on ocular myasthenia gravis in children prepared with a formula from Traditional Chinese Medicine. J TRADIT CHIN MED 2017; 37:546-553. [PMID: 32188214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
OBJECTIVE To investigate the effect of Jianpiyiqi granule, prepared according to a Traditional Chinese Medicine (TCM) formula, on the ocular type of myasthenia gravis (MG) caused by a defect in synaptic transmission at the neuromuscular junction. METHODS A total of 155 children with ocular MG were recruited from January 2008 to January 2015. All individuals received ineffective glucocorticoid treatment prior to admission, and were given Jianpiyiqi granules (two doses per day) for 12 months. Plasma levels of acetylcholine receptor autoantibodies (AChR-Ab), cytokines, immune parameters and clinical score were analyzed. RESULTS After intervention with Jianpiyiqi granule for 12 months, the levels of cytokines [including interleukin (IL)-6, IL-12, IL-17], immune parameters [including immunoglobulin G (IgG), IgM, free triiodothyronine, free thyroxine] and AChR-Ab were significantly decreased (P = 0.042, P = 0.049, P = 0.011, P = 0.02, P = 0.04, P = 0.03, P = 0.01; F = 21.60, P = 0.000). In contrast, IL-4 levels were significantly increased (P = 0.049). The absolute clinical score after treatment declined significantly compared with before treatment (F = 33.24, P = 0.000). The effective cure rate and the total effective rate gradually increased to a maximum of 149 (96.2%) and 151 (97.4%) in MG patients after 12 months of treatment, respectively. CONCLUSION The Jianpiyiqi granule treatment lowered AChR-Ab levels and improved cytokine and other immune parameter levels, which suggests that the granule could be an ancillary treatment for ocular MG in children caused by a defect in synaptic transmission at the neuromuscular junction.
Collapse
Affiliation(s)
- Guoyan Qi
- Center of Treatment of Myasthenia Gravis, First Hospital of Shijiazhuang, Shijiazhuang 050011, China
| | - Peng Liu
- Center of Treatment of Myasthenia Gravis, First Hospital of Shijiazhuang, Shijiazhuang 050011, China
| | - Shanshan Gu
- Center of Treatment of Myasthenia Gravis, First Hospital of Shijiazhuang, Shijiazhuang 050011, China
| | - Hongxia Yang
- Center of Treatment of Myasthenia Gravis, First Hospital of Shijiazhuang, Shijiazhuang 050011, China
| | - Huimin Dong
- Center of Treatment of Myasthenia Gravis, First Hospital of Shijiazhuang, Shijiazhuang 050011, China
| | - Yinping Xue
- Center of Treatment of Myasthenia Gravis, First Hospital of Shijiazhuang, Shijiazhuang 050011, China
| |
Collapse
|
24
|
Qi G, Liu P, Dong H, Gu S, Yang H, Xue Y. Therapeutic Potential of Docetaxel plus Cisplatin Chemotherapy for Myasthenia Gravis Patients with Metastatic Thymoma. TOHOKU J EXP MED 2017; 241:281-286. [PMID: 28381664 DOI: 10.1620/tjem.241.281] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The prognosis of myasthenia gravis (MG) in association with invasive or metastatic thymoma is usually worse, and therapeutic options are quite limited. Here, we retrospectively reported the therapeutic effect of docetaxel plus cisplatin (docetaxel/cisplatin) chemotherapy in 7 MG patients with metastatic thymoma. Previously, all patients underwent thymectomy at the first onset of thymoma. After the metastasis of thymoma, none of the patients received thymectomy due to unresectable conditions after surgeon's evaluation for great risk of myasthenic crisis (n = 5) or patients' refusal (n = 2). All patients received docetaxel (75 mg/m2) and cisplatin (70 mg/m2) on day 1 (d1) every 21 days, with the cycle ranging from 1 to 4. After docetaxel/cisplatin chemotherapy, one patient achieved partial response, and 6 with stable disease of the tumors. The clinical symptoms of MG were alleviated in all patients, 2 with complete remission and the other 5 with marked improvement. Myelosuppression was the major adverse event, occurring in 2 patients (grade II and IV). MG relapse occurred in one patient during the follow-up. Our study presented a series of MG patients with metastatic thymoma who underwent docetaxel/cisplatin chemotherapy. Besides the improved/stabilized thymoma, markedly improvement of MG with the tolerable adverse events was achieved. Docetaxel/cisplatin chemotherapy appears to be an effective treatment for selected patients with MG in association with unresectable metastatic thymoma. Further follow-up of these patients and additional subjects will be needed to determine whether the therapeutic benefits are durable.
Collapse
Affiliation(s)
- Guoyan Qi
- Myasthenia Gravis Treatment Center of Hebei Province, First Hospital of Shijiazhuang
| | | | | | | | | | | |
Collapse
|
25
|
Qi G, Liu P, Dong H, Gu S, Yang H, Xue Y. Metastatic Thymoma-Associated Myasthenia Gravis: Favorable Response to Steroid Pulse Therapy Plus Immunosuppressive Agent. Med Sci Monit 2017; 23:1217-1223. [PMID: 28278141 PMCID: PMC5356615 DOI: 10.12659/msm.902442] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
BACKGROUND Our study retrospectively reviewed the therapeutic effect of steroid pulse therapy in combination with an immunosuppressive agent in myasthenia gravis (MG) patients with metastatic thymoma. MATERIAL AND METHODS MG patients with metastatic thymoma that underwent methylprednisolone pulse therapy plus cyclophosphamide were retrospectively analyzed. Patients initially received methylprednisolone pulse therapy followed by oral methylprednisolone. Cyclophosphamide was prescribed simultaneously at the beginning of treatment. Clinical outcomes, including therapeutic efficacy and adverse effects of MG and thymoma, were assessed. RESULTS Twelve patients were recruited. According to histological classification, 4 cases were type B2 thymoma, 3 were type B3, 2 were type B1, and 1 was type AB. After combined treatment for 15 days, both the thymoma and MG responded dramatically to high-dose methylprednisolone plus cyclophosphamide. The symptoms of MG were improved in all patients, with marked improvement in 6 patients and basic remission in 4. Interestingly, complete remission of thymoma was achieved in 5 patients and partial remission in 7 patients. Myasthenic crisis was observed in 1 patient and was relieved after intubation and ventilation. Adverse reactions were observed in 7 patients (58.3%), most commonly infections, and all were resolved without discontinuation of therapy. During the follow-up, all patients were stabilized except for 1 with pleural metastasis who received further treatment and another 1 who died from myasthenic crisis. CONCLUSIONS The present study in a series of MG patients with metastatic thymoma indicated that steroid pulse therapy in combination with immunosuppressive agents was an effective and well-tolerated for treatment of both metastatic thymoma and MG. Glucocorticoid pulse therapy plus immunosuppressive agents should therefore be considered in MG patients with metastatic thymoma.
Collapse
Affiliation(s)
- Guoyan Qi
- Myasthenia Gravis Treatment Center of Hebei Province, 1st Hospital of Shijiazhuang, Shijiazhuang, Hebei, China (mainland)
| | - Peng Liu
- Myasthenia Gravis Treatment Center of Hebei Province, 1st Hospital of Shijiazhuang, Shijiazhuang, Hebei, China (mainland)
| | - Huimin Dong
- Myasthenia Gravis Treatment Center of Hebei Province, 1st Hospital of Shijiazhuang, Shijiazhuang, Hebei, China (mainland)
| | - Shanshan Gu
- Myasthenia Gravis Treatment Center of Hebei Province, 1st Hospital of Shijiazhuang, Shijiazhuang, Hebei, China (mainland)
| | - Hongxia Yang
- Myasthenia Gravis Treatment Center of Hebei Province, 1st Hospital of Shijiazhuang, Shijiazhuang, Hebei, China (mainland)
| | - Yinping Xue
- Myasthenia Gravis Treatment Center of Hebei Province, 1st Hospital of Shijiazhuang, Shijiazhuang, Hebei, China (mainland)
| |
Collapse
|
26
|
Zhang Z, Su D, Zhu P, Bi X, Qi G, Wu X. Effect of different luteal support schemes on clinical outcome in frozen-thawed embryos transfer cycles. CLIN EXP OBSTET GYN 2016. [DOI: 10.12891/ceog2088.2016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
27
|
Zhang Z, Su D, Zhu P, Bi X, Qi G, Wu X. Effect of different luteal support schemes on clinical outcome in frozen-thawed embryos transfer cycles. CLIN EXP OBSTET GYN 2016; 43:486-489. [PMID: 29734532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
OBJECTIVE To evaluate the clinical outcome of frozen-thawed embryo transfer (FET) when using different luteal support schemes. STUDY DESIGN Retrospective analysis of FET cycles was performed from June 2013 and December 2013. Infertile women, who underwent FET cycles utilizing embryos cryopreserved on day 3 post-insemination following an initial fresh IVF cycle. Patients were divided into three groups according to the luteal support scheme. Grade A (oral administration of progesterone, n=156), Group B (vaginal administration of progesterone, n=345), Group C (dissolved progesterone in oil with intramuscular infection, n=885), and group C was divided into two subgroups according to with (subgroup Cl, n=521) or without (subgroup C2 ,n=364) human chorionic gonadotrophi (hCG) injected intramuscularly. The authors compared patients' characteristics and the pregnancy outcomes of each group. RESULTS There was no difference in the patient characteristics of each group. There was no difference in the implantation rate or clinical and ongoing pregnancy rate among oral, vaginal, and intramuscular progesterone groups. The abortion and ectopic pregnancy rates were not significantly different among the three groups. CONCLUSION Oral progesterone in the FET cycles is convenient and has similar pregnancy outcomes compared with intramuscular or vaginal administration.
Collapse
|
28
|
Qi G, Gu S, Liu P, Yang H, Dong H. Effects of combined traditional Chinese medicine with immunosuppressive agents for patients with myasthenia gravis. Int J Clin Exp Med 2015; 8:19044-19050. [PMID: 26770531 PMCID: PMC4694431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2015] [Accepted: 08/27/2015] [Indexed: 06/05/2023]
Abstract
Myasthenia gravis (MG) is a kind of autoimmune disease induced by transferring dysfunction of neuromuscular junction. In the present study, we developed an integrated therapy combined with traditional Chinese medicine and immuno suppressive agents to seek for an effective treatment of MG. 220 MG patients were randomly divided into two groups with different therapies. Plasma levels of acetylcholine receptors antibodies (AchRAb) and CD4(+)CD25(+) regulatory T cells (CD4(+)CD25(+)Treg) were conducted through ELISA and flow cytometry. The amount of AchRAb (8.52±0.96 vs. 5.22±0.46) and CD4(+)CD25(+)Treg (1.94±1.21 vs. 3.21±0.96) in Group A receiving integrated therapy were significantly improved compared with Group B; the clinical performance of group treated with the integrated therapy was also much better. The integrated therapy in the present study could significantly improve the condition of MG with high recovery rate and low recurrence rate, which can be employed in future clinical treatment of MG.
Collapse
Affiliation(s)
- Guoyan Qi
- First Hospital of Shijiazhuang, Center of Treatment of Myasthenia Gravis Hebei Province, China
| | - Shanshan Gu
- First Hospital of Shijiazhuang, Center of Treatment of Myasthenia Gravis Hebei Province, China
| | - Peng Liu
- First Hospital of Shijiazhuang, Center of Treatment of Myasthenia Gravis Hebei Province, China
| | - Hongxia Yang
- First Hospital of Shijiazhuang, Center of Treatment of Myasthenia Gravis Hebei Province, China
| | - Huimin Dong
- First Hospital of Shijiazhuang, Center of Treatment of Myasthenia Gravis Hebei Province, China
| |
Collapse
|
29
|
Al-Marri MJ, Khader MM, Tawfik M, Qi G, Giannelis EP. CO₂ sorption kinetics of scaled-up polyethylenimine-functionalized mesoporous silica sorbent. Langmuir 2015; 31:3569-3576. [PMID: 25764385 DOI: 10.1021/acs.langmuir.5b00189] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Two CO2 solid sorbents based on polyethylenimine, PEI (M(n) ∼ 423 and 10K), impregnated into mesoporous silica (MPS) foam prepared in kilogram quantities via a scale-up process were synthesized and systematically characterized by a range of analytical and surface techniques. The mesoporous silica sorbent impregnated with lower molecular weight PEI, PEI-423/MPS, showed higher capacity toward CO2 sorption than the sorbent functionalized with the higher molecular weight PEI (PEI-10K/MPS). On the other hand, PEI-10K/MPS exhibited higher thermal stability than PEI-423/MPS. The kinetics of CO2 adsorption on both PEI/MPS fitted well with a double-exponential model. According to this model CO2 adsorption can be divided into two steps: the first is fast and is attributed to CO2 adsorption on the sorbent surface; the second is slower and can be related to the diffusion of CO2 within and between the mesoporous particles. In contrast, the desorption process obeyed first-order kinetics with activation energies of 64.3 and 140.7 kJ mol(-1) for PEI-423/MPS and PEI-10K/MPS, respectively. These studies suggest that the selection of amine is critical as it affects not only sorbent capacity and stability but also the energy penalty associated with sorbent regeneration.
Collapse
Affiliation(s)
- M J Al-Marri
- †Gas Processing Center, College of Engineering, Qatar University, P.O. Box 2713, Doha, Qatar
| | - M M Khader
- †Gas Processing Center, College of Engineering, Qatar University, P.O. Box 2713, Doha, Qatar
| | - M Tawfik
- †Gas Processing Center, College of Engineering, Qatar University, P.O. Box 2713, Doha, Qatar
| | - G Qi
- ‡Department of Materials Science and Engineering, Cornell University, Ithaca, New York 14853, United States
| | - E P Giannelis
- ‡Department of Materials Science and Engineering, Cornell University, Ithaca, New York 14853, United States
| |
Collapse
|
30
|
Khader MM, Al-Marri MJ, Ali S, Qi G, Giannelis EP. Adsorption of CO<sub>2</sub> on Polyethyleneimine 10k—<i>Mesoporous silica</i> Sorbent: XPS and TGA Studies. ACTA ACUST UNITED AC 2015. [DOI: 10.4236/ajac.2015.64026] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
31
|
Abstract
Bio-inspired laminated graphite nanosheets/copper composites with modified mechanical properties.
Collapse
Affiliation(s)
- P. Wang
- Shanghai Hiwave Advanced Materials Technology Co., Ltd
- Shanghai 200240
- P. R. China
| | - W. Liu
- Shanghai Hiwave Advanced Materials Technology Co., Ltd
- Shanghai 200240
- P. R. China
| | - L. Chen
- Shanghai Hiwave Advanced Materials Technology Co., Ltd
- Shanghai 200240
- P. R. China
| | - C. Mu
- Wenzhou Hongfeng Electrical Alloy Co., Ltd
- Wenzhou 325603
- P. R. China
| | - G. Qi
- Wenzhou Hongfeng Electrical Alloy Co., Ltd
- Wenzhou 325603
- P. R. China
| | - F. Bian
- Shanghai Synchrotron Radiation Facility
- Shanghai Institute of Applied Physics Chinese Academy of Sciences
- Shanghai 201204
- P. R. China
| |
Collapse
|
32
|
Tam AMW, Qi G, Srivastava AK, Wang XQ, Fan F, Chigrinov VG, Kwok HS. Enhanced performance configuration for fast-switching deformed helix ferroelectric liquid crystal continuous tunable Lyot filter. Appl Opt 2014; 53:3787-3795. [PMID: 24921146 DOI: 10.1364/ao.53.003787] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/04/2014] [Accepted: 05/05/2014] [Indexed: 06/03/2023]
Abstract
In this paper, we present a novel design configuration of double DHFLC wave plate continuous tunable Lyot filter, which exhibits a rapid response time of 185 μs, while the high-contrast ratio between the passband and stop band is maintained throughout a wide tunable range. A DHFLC tunable filter with a high-contrast ratio is attractive for realizing high-speed optical processing devices, such as multispectral and hyperspectral imaging systems, real-time remote sensing, field sequential color display, and wavelength demultiplexing in the metro network. In this work, an experimental prototype for a single-stage DHFLC Lyot filter of this design has been fabricated using photoalignment technology. We have demonstrated that the filter has a continuous tunable range of 30 nm for a blue wavelength, 45 nm for a green wavelength, and more than 50 nm for a red wavelength when the applied voltage gradually increases from 0 to 8 V. Within this tunable range, the contrast ratio of the proposed double wave plate configuration is maintained above 20 with small deviation in the transmittance level. Simulation and experimental results showed the proposed double DHFLC wave plate configuration enhances the contrast ratio of the tunable filter and, thus, increases the tunable range of the filter when compared with the Lyot filter using a single DHFLC wave plate. Moreover, we have proposed a polarization insensitive configuration for which the efficiency of the existing prototype can theoretically be doubled by the use of polarization beam splitters.
Collapse
|
33
|
Wang H, Zhao Y, Ma J, Zhang G, Mu Y, Qi G, Fang Z, Wang L, Fan Q, Ma Z. Short Communication The genetic variant rs401681C/T is associated with the risk of non-small cell lung cancer in a Chinese mainland population. Genet Mol Res 2013; 12:67-73. [DOI: 10.4238/2013.january.22.5] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
34
|
Ren J, Yang M, Qi G, Zheng J, Jia L, Cheng J, Tian C, Li H, Lin X, Du J. Proinflammatory protein CARD9 is essential for infiltration of monocytic fibroblast precursors and cardiac fibrosis caused by Angiotensin II infusion. Am J Hypertens 2011; 24:701-7. [PMID: 21436792 PMCID: PMC3139445 DOI: 10.1038/ajh.2011.42] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Background Angiotensin II (Ang II)–induced cardiac remodeling with the underlying mechanisms involving inflammation and fibrosis has been well documented. Cytosolic adaptor caspase recruitment domain 9 (CARD9) has been implicated in the innate immune response. We aimed to examine the role of CARD9 in inflammation and cardiac fibrosis induced by Ang II. Methods Two-month-old CARD9-deficient (CARD9−/−) and wild-type (WT) male mice were infused with Ang II (1,500 ng/kg/min) or saline for 7 days. Heart sections were stained with hematoxylin and eosin and Masson trichrome and examined by immunohistochemistry; and activity and protein levels were measured in macrophages obtained from mice. Results WT mice with Ang II infusion showed a marked increase in CARD9+ macrophages in the heart, but CARD9−/− mice showed significantly suppressed macrophage infiltration and expression of proinflammatory cytokines, including interleukin-1β (IL-1β) and connective tissue growth factor (CTGF). Importantly, Ang II–induced cardiac fibrosis (extracellular matrix and collagen I deposition) was diminished in CARD9−/− hearts, as was the expression of transforming growth factor-β (TGF-β) and level of myofibroblasts positive for α-smooth muscle actin (α-SMA). Furthermore, Ang II activation of nuclear factor-κB (NF-κB), JNK and p38 mitogen-activated protein kinases (MAPKs) in WT macrophages was reduced in CARD9−/− macrophages. Conclusion CARD9 plays an important role in regulating cardiac inflammation and fibrosis in response to elevated Ang II.
Collapse
|
35
|
Qi G, Lan N, Ma X, Yu Z, Zhao X. Controlling Myzus persicae with recombinant endophytic fungi Chaetomium globosum expressing Pinellia ternata agglutinin. J Appl Microbiol 2011; 110:1314-22. [DOI: 10.1111/j.1365-2672.2011.04985.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
Qi G, Lu J, Zhang P, Li J, Zhu F, Chen J, Liu Y, Yu Z, Zhao X. The cry1Ac gene of Bacillus thuringiensis ZQ-89 encodes a toxin against long-horned beetle adult. J Appl Microbiol 2011; 110:1224-34. [DOI: 10.1111/j.1365-2672.2011.04974.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Kwong W, Neilson AL, Hamilton RM, Chiu CC, Stephenson EA, Gross GJ, Soucie L, Kirsh JA, xian-hui Z, Bao-peng T, Jin-xin L, Yu Z, Yan-yi Z, Jiang-hua Z, Hirahara T, Sugawara Y, Suga C, Ako J, Momomura S, Ardashev AV, Zhelyakov EG, Konev AV, Rybachenko MS, Belenkov YN, Bai R, Di Biase L, Santangeli P, Saenz LC, Verma A, Sanchez J, Tondo C, Natale A, Safari F, Hajizadeh S, Mani A, Khoshbaten A, Foadoddini M, Forush SS, Bayat G, Kim SH, Chong D, Ching CK, Liew R, Galalardin, Khin MW, Teo WS, Chong D, Tan BY, Liew R, Ching CK, Teo WS, Sakamoto T, Al Mehairi M, Al Ghamdi SA, Dagriri K, Al Fagih A, Selvaraj R, Ezhumalai B, Satheesh S, Ajit A, Gobu P, Balachander J, Liu XQ, Zhou X, Yang G, Zhong GZ, Shi L, Tian Y, Li YB, Wang AH, Yang XC, Takenaka S, Ozaki H, Nakamura M, Otsuka M, Tsurumi Y, Nolker G, Gutleben KJ, Ritscher G, Sinha AM, Muntean B, Heintze J, Vogt J, Brachmann J, Horstkotte D, Katsuyuki T, Katsuyuki T, McGrew F, Johnson E, Coppess M, Fan I, Li S, Zhiyu L, Zengzhang L, Xianbin L, Yuehui Y, Min L, Shu-long Z, Dong C, Zhi-tao Z, Xian-jing W, Ying-xue D, Shu-Long Z, Dong C, Zhi-Tao Z, Xian-Jing W, Ying-Xue D, Liu P, Guo JH, Zhang Z, Li J, Liu HG, Zhang HC, Zvereva V, Rillig A, Meyerfeldt U, Jung W, Wei L, Qi G, Zhang Q, Xia Y, Doi A, Satomi K, Nakajima I, Makimoto H, Yokoyama T, Yamada Y, Okamura H, Noda T, Aiba T, Shimizu W, Aihara N, Kamakura S, Li Z, Zhao QY, Huang CX, Doi A, Satomi K, Nakajima I, Makimoto H, Yokoyama T, Yamada Y, Okamura H, Noda T, Aiba T, Shimizu W, Aihara N, Kamakura S, Min-Seok C, Jeong-Wook P, Young-Woong H, Sung-Eun P, Jae-Sun U, Yong-Seog O, Woo-Seung S, Ji-Hoon K, Seong-Won J, Man-Young L, Tae-Ho R, Uhm JS, Oh YS, Choi MS, Park JW, Ha YW, Park SE, Jang SW, Shin WS, Kim JH, Lee MY, Rho TH, Nielsen JB, Olesen MS, Tango M, Haunso S, Holst AG, Svendsen JH, Poci D, Thogersen AM, Riahi S, Linde P, Edvardsson N, Khoo CW, Krishnamoorthy S, Dwivedi G, Balakrishnan B, Lim HS, Lip GYH, Khoo CW, Krishnamoorthy S, Dwivedi G, Balakrishnan B, Lim HS, Lip GYH, D'Ascia S, D'ascia C, Marino V, Chiariello M, Santulli G, Music L, Anderson K, Benzaquen BS, Saponieri C, Yassin H, Fridman V, Vasavada BC, Turitto G, El-Sherif N, Saponieri C, Prabhu H, Yassin H, Fridman V, Huang Y, Vasavada BC, Turitto G, El-Sherif N, Ortega MC, Sosa ESH, Ugalde AN, Al Jamil A, Abu Siddique M, Haque KMHSS, Suga C, Hirahara T, Sugawara Y, Ako J, Momomura SI, Mlynarski R, Mlynarska A, Ilczuk G, Mlynarski R, Mlynarska A, Wilczek J, Mlynarska A, Mlynarski R, Wilczek J, Mlynarska A, Mlynarski R, Wilczek J, Sosnowski M, Kohno R, Abe H, Nagatomo T, Oginosawa Y, Minamiguchi H, Otsuji Y, Kohno R, Abe H, Minamiguchi H, Oginosawa Y, Nagatomo T, Otsuji Y, Minamiguchi H, Abe H, Kohno R, Oginosawa Y, Otsuji Y, Ekinci S, Yesil M, Bayata S, Vurgun VK, Arikan E, Postaci N, Xiaoqing R, Jielin P, Shu Z, Liang M, Fangzheng W, Takahashi K, Tokano T, Nakazato Y, Doi S, Shiozawa T, Konishi H, Hiki M, Kato Y, Komatsu S, Takahashi S, Kubota N, Tamura H, Suwa S, Ohki M, Katsumata T, Kizu K, Bito F, Sumiyoshi M, Juntendo HD, Yamada Y, Okamura H, Nakajima I, Doi A, Makimoto H, Yukoyama T, Noda T, Satomi K, Aiba T, Shimizu W, Aihara N, Kamakura S, Perna F, Leo M, Leccisotti L, Casella M, Pelargonio G, Lago M, Bencardino G, Narducci ML, Russo E, Santangeli P, Giordano A, Bellocci F, Song T, Yang J, Huang C, Zhang J, Huang C, Wu P, Yang J, Song T, Chen Y, Fan X, Wang T, Wang X, Tang Y, Wu P, Huang CX, Zhang J, Fan XR, Chen YJ, Li XW, Yang J, Song T, Chiu CC, Buescher T, Obias-Manno D, Yoo CJ, Huh J, Ortega MC, Nakanishi H, Hirata A, Wada M, Kashiwase K, Okada M, Ueda Y, Su D, Niu XL, Song AQ, Kohno R, Abe H, Minamiguchi H, Oginosawa Y, Nagatomo T, Otsuji Y, Fujii S, Yambe Y, Shiiba K, Sakakibara M, Takenaka S, Watanabe A, Wada T, Koide Y, Ikeda M, Toda H, Hashimoto K, Terasaka R, Nakahama M, Wada T, Watanabe A, Koide Y, Ikeda M, Toda H, Hashimoto K, Terasaka R, Nakahama M, Okada Y, Mizuno H, Ide H, Ueno T, Kogaki S, Ozono K, Nanto S, Statescu C, Bercea R, Sascau RA, Georgescu CA, Ortega MC, Athanas E, Ortega MC, Athanas E, Mironov NY, Bakalov SA, Jarova EA, Rodionova ES, Mironova NA, Kim J, Ahn MS, Han DC, Choo JTL, Chen CK, Tan TH, Ong KK, Kam R, Curnis A, Bontempi L, Coppola G, Cerini M, Vassanelli F, Lipari A, Gennaro F, Pagnoni C, Ashofair N, Cas LD, Gourineni V, Wong KL, Davoudi R, Hamid N, Chong D, Yew TB, Liew R, Keong CC, Siong TW, Fuke E, Shimizu H, Kimura S, Hao K, Watanabe R, Seo JB, Chung WY, Kim SH, Kim MA, Zo ZH, Krishinan S, Skuratova NA, Belyaeva LM, Bae MH, Lee JH, Lee HS, Yang DH, Park HS, Cho Y, Chae SC, Jun JE, Rychkova LV, Dolgikh VV, Zurbanova LV, Zurbanov AV, Aleksanyan A, Matevosyan A, Podosyan G, Zelveian P, Aleksanyan A, Podosyan G, Matevosyan A, Zelveian P, Choi HO, Nam GB, Kim YR, Kim KH, Kim SH, Choi KJ, Kim YH, Pakpahan HAP, Wei D, Qizhu T, Xiaofei Y, Kai G, Siting F, Ji H, Sato A, Tanabe Y, Hayashi Y, Yoshida T, Ito E, Chinushi M, Hasegawa K, Yagihara N, Iijima K, Izumi D, Watanabe H, Furushima H, Aizawa Y, Dong YX, Dong YX, Burnett JC, Chen HH, Sandberg S, Zhang Y, Chen PS, Cha YM, Mlynarski R, Mlynarska A, Wilczek J, Sosnowski M, Zhou XH, Tang BP, Li JX, Zhang Y, Li YD, Zhang JH, Arsenos P, Gatzoulis K, Gialernios T, Dilaveris P, Sideris S, Archontakis S, Tsiachris D, Christodoulos S, Feng Z, Baogui S, Li L, Ming L, Bai R, Di Biase L, Mohanty P, Hesselson AB, De Ruvo E, Gallagher PL, Minati M, Natale LCA, Tomassoni GF, Gan T, Tang B, Xu G, Li J, Zhang Y, Zhou X, Zhang Y, Hosoda J, Ishikawa T, Matsushita K, Matsumoto K, Kimura Y, Miyamoto M, Sugano T, Ishigami T, Uchino K, Kimura K, Umemura S, Nakajima I, Noda T, Shimizu W, Yokoyama T, Makimoto H, Doi A, Yamada Y, Okamura H, Satomi K, Aiba T, Aihara N, Kamakura S, Nakajima I, Noda T, Shimizu W, Kurita T, Yokoyama T, Makimoto H, Doi A, Yamada Y, Okamura H, Satomi K, Aiba T, Aihara N, Kamakura S, Wang T, Huang CX, Wang T, Huang CX, Ruan L, Zhang C, Cai S, Bai R, Liu N, Ruan Y, Quan X, Kang JK, Kim NY, Park SH, Lee JH, Park HS, Cho Y, Chae SC, Jun JE, Park WH, Sapelnikov OV, Latypov RS, Grishin IR, Mareev YV, Saidova MA, Akchurin RS, Arsenos P, Gatzoulis K, Manis G, Dilaveris P, Archontakis S, Tsiachris D, Mytas D, Papafanis T, Papavasileiou MV, Stefanadis C, Ren LN, Fang XH, Wang YQ, Qi GX, Zeng QX, Zheng ZT, Zhong JQ, Wang YL, Liu HZ, Liu DL, Meng XL, Li JS, Zhang Y, Liu HZ, Zhong JQ, Zeng QX, Liu DL, Meng XL, Li JS, Su GY, Wang J, Zhang Y, Liu HZ, Zhong JQ, Zeng QX, Wang YL, Liu DL, Meng XL, Li JS, Su GY, Zhang Y, Li JS, Zhong JQ, Zeng QX, Liu HZ, Su GY, Zhang Y, Li JS, Zhong JQ, Zeng QX, Liu HZ, Meng XL, Liu DL, Su GY, Zhang Y, Li JS, Zhong JQ, Zeng QX, Liu HZ, Meng XL, Liu DL, Su GY, Zhang Y, Nicolson WB, Kundu S, Tyagi N, Meatcher PDS, Yusuf S, Jeilan M, Stafford PJ, Sandilands AJ, Loke I, Ng GA, Nicolson WB, Kundu S, Tyagi N, Meatcher PDS, Yusuf S, Jeilan M, Stafford PJ, Sandilands AJ, Loke I, Ng GA, Solak Y, Gul EE, Atalay H, Abdulhalikov T, Kayrak M, Turk S, Kang JK, Kim NY, Park SH, Lee JH, Park HS, Cho Y, Chae SC, Jun JE, Park WH, Belyaeva LM, Skuratova NA, Pogodina AV, Dolgikh VV, Valjavskaja OV, Zurbanov AV, Chen YX, Luo NS, Wang JF, Zhang S, Ishimaru S, Miyakawa M, Kakinoki R, Tadokoro M, Kitani S, Sugaya T, Nishimura K, Igarashi T, Okabayashi H, Furuya J, Igarashi Y, Igarashi K, Su T, Winlaw D, Chard R, Nicholson I, Sholler G, Lau K, Sun Q, Cheng KP, Cheng R, Hua W, Pu JL, Zhang S, Lim CP, Chan LL, Teo LW, Kwok BWK, Sim DKL, Ching CK, Lim CP, Chan LL, Teo LW, Kwok BWK, Sim DKL, Ching CK, Curnis A, Bontempi L, Cerini M, Lipari A, Vassanelli F, Pagnoni C, Ashofair N, Moneghini D, Cestari R, Cas LD, Al Fagih A, Al Shurafa H, Al Ghamdi S, Dagriri K, Al Khadra A, Iijima K, Chinushi M, Hasegawa K, Yagihara N, Sato A, Izumi D, Watanabe H, Furushima H, Aizawa Y, Furushima H, Chinushi M, Iijima K, Izumi D, Hasegawa K, Yagihara N, Watanabe H, Sato A, Aizawa Y, Agacdiken A, Yalug I, Vural A, Celikyurt U, Ural D, Aker T, Agacdiken A, Yalug I, Vural A, Celikyurt U, Ural D, Aker T, Heintze J, Schloss E, Auricchio A, Zeng C, Sterns L, Farooqi F, Kamdar R, Adhya S, Bayne S, Jackson T, Pollock L, Sterns L, Gall N, Murgatroyd F, Guo Y, Wang Y, Yang T, Zhu P, Liu H, Zhao Y, Zhang L, Gao W, Gao M. Poster presentation. Europace 2011. [DOI: 10.1093/europace/euq492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
38
|
Yang H, Dib HH, Zhu M, Qi G, Zhang X. Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China. Health Policy Plan 2009; 25:219-29. [DOI: 10.1093/heapol/czp056] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Qi G, Li JT, Ruan QP, Yang J, Su ZX. An optimised, small-scale preparation of high-quality RNA from dry seeds of Davidia involucrata. Phytochem Anal 2009; 20:139-142. [PMID: 19140111 DOI: 10.1002/pca.1108] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
INTRODUCTION The dormancy of Davidia involucrata seeds normally lasts for an extended period of time and because of this unique property the species is an excellent model for studying the molecular mechanisms of plant dormancy. The use of minimal plant material is desirable for RNA extraction since D. involucrata is a rare plant and it is relatively difficult to collect large amounts of seeds in order to perform molecular biology studies. OBJECTIVE To improve the quality of RNA obtained from seeds of D. involucrata by eliminating the oxidation of polyphenols during extraction and by preventing polysaccharides and other impurities from being extracted. METHODS A previously described method was modified by the addition of 4% (w/v) poly(N-vinyl-2-pyrrolidone) to the dry seeds during grinding and by adding 5% (v/v) beta-mercaptoethanol and 28% (v/v) ethanol to the extraction buffer. Two further centrifugation steps (5000 and 8000 rpm) were utilised and one-seventh volume of ethanol was incubated with the supernatant at 4 degrees C for 2-3 h prior to the precipitation of RNA. RESULTS Following these modifications, an effective method was established for total RNA extraction from a small amount of dry seeds of D. involucrata. The isolated RNA was shown to have high purity and integrity by gel electrophoresis and spectrophotometry, and was confirmed to be suitable for RT-PCR and the construction of cDNA libraries. CONCLUSION The modified method reduced the amount of seeds required for extraction of total DNA and was beneficial for preserving the endangered species.
Collapse
Affiliation(s)
- G Qi
- Sichuan Provincial key Laboratory of Environmental Science and Biological Diversity Conservation, China West Normal University, Nanchong, Sichuan, People's Republic of China
| | | | | | | | | |
Collapse
|
40
|
Abstract
The DNA-packaging pRNA of bacterial virus phi29, which forms dimers and then hexamers, contains two independent tightly self-folded domains. Circularly permuted pRNAs were constructed without impacting pRNA folding. Connecting the pRNA 5'/3' ends with variable sequences did not disturb its folding and function. These unique features, which help prevent two common problems - exonuclease degradation and misfolding in the cell, make pRNA an ideal vector to carry therapeutic RNAs. A pRNA-based vector was designed to carry hammerhead ribozymes that cleave the hepatitis B virus (HBV) polyA signal. The chimeric HBV-targeting ribozyme was connected to the pRNA 5'/3' ends as circularly permuted pRNA. Two cis-cleaving ribozymes were used to flank and process the chimeric ribozyme. The hammerhead ribozyme including its two arms for HBV targeting was able to fold correctly while escorted by the pRNA. The chimeric ribozyme cleaved the polyA signal of HBV mRNA in vitro almost completely. Cell culture studies showed that the chimeric ribozyme was able to enhance the inhibition of HBV replication when compared with the ribozyme not escorted by pRNA, as demonstrated by Northern blot and e-antigen assays. pRNA could also carry another hammerhead ribozyme to cleave other RNA substrate. These findings suggest that pRNA can be used as a vector for imparting stability to ribozymes, antisense, and other therapeutic RNA molecules in vivo.
Collapse
Affiliation(s)
- S Hoeprich
- Department of Pathobiology and Cancer Research Center, Purdue University, west Lafayette, IN 47907, USA
| | | | | | | | | | | | | |
Collapse
|
41
|
Qi G, Goloubev MY, DiBianca FA, Samant S. On modelling the kinestatic charge detector for digital radiographic diagnostic and portal imaging. J Med Eng Technol 2002; 26:193-8. [PMID: 12487709 DOI: 10.1080/03091900210142486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
The kinestatic charge detection (KCD) principle has been a digital radiography technique for more than a decade. The advances of the KCD technique have gone from diagnostic imaging to portal imaging. However, little work has been done on understanding the selection of key KCD parameters and relationships between them. In the present study, an engineering model was established that could be used to optimize the placements of key parameters in terms of KCD system mechanical design. In the proposed KCD engineering model, the basic energy conservation law was applied to the process of ion transmission. It allows for the computation of the KCD design parameters such as the optimum grid placement, high voltage board tilt angle and grid wire space, as well as to provide recommendations on high voltage board and electric potentials and their ratio.
Collapse
Affiliation(s)
- G Qi
- Department of Mechanical Engineering, The University of Memphis, Memphis, Tennessee, USA
| | | | | | | |
Collapse
|
42
|
Qi G, Jiang P, Xu H. [Methods for making human sectional specimens]. Hunan Yi Ke Da Xue Xue Bao 2002; 24:inside back cover. [PMID: 11938801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
|
43
|
He B, Zhao M, Qi G. [Activation of transcription factors and induction of cytokines from macrophages in chronic obstructive pulmonary disease]. Zhonghua Yi Xue Za Zhi 2001; 81:1360-4. [PMID: 11930628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Abstract
OBJECTIVE To investigate the activation of transcription factors and induction of cytokines from alveolar macrophages in chronic obstructive pulmonary disease (COPD). METHODS Alveolar macrophages were collected by fibrobronchoscopy from 8 patients with chronic bronchitis, 8 patients with COPD, and 8 healthy volunteers. All patients were at stable stage. The macrophages thus collected were cultured and stimulated with lipopolysaccharide (LPS, 10 micrograms/ml). The IL-8, IL-1 beta, TNF alpha and IL-6 thus produced were measured by ELISA in the supernatant. Nuclear factor-kappa B (NF kappa B), activator protein-1 (AP-1), AP-2 and AP-3 were detected by electrophoretic mobility shift assay. RESULTS The concentration of IL-8 released from macrophages of patients with COPD at stable stage before LPS stimulation was about 3 times higher than that in the healthy control (F = 4.34, P < 0.05). The concentration of IL-8 released from macrophages in patients with COPD was increased further after LPS stimulation in comparison to that in healthy controls(F = 3.56, P < 0.05). The concentration of IL-1 beta and that of TNF alpha released from macrophages of COPD patients were further increased after LPS stimulation (P < 0.05) in the COPD patients, but there was no difference in the concentration of IL-1 beta and between the control and COPD patients before LPS stimulation. The constitutive activity of AP-1 and the activity of NF kappa B induced by LPS were higher in the patients with COPD than in the controls. CONCLUSION The alverlar macrophages of patients with COPD at stable stage may release higher concentration of IL-8 and IL-1 beta. LPS stimulation increases the release of IL-1 beta and TNF alpha of alveolar macrophages. Enhancement of activity of NF kappa B and AP-1 may positively regulate the production of IL-8 and IL-1 beta in the airflow obstruction.
Collapse
Affiliation(s)
- B He
- Pulmonary Division, Department of Internal Medicine, Peking University, Third Hospital, Beijing 100083, China
| | | | | |
Collapse
|
44
|
|
45
|
Qi G, Zhang L, Xie WL, Chen XY, Li JS. Protective effect of gypenosides on DNA and RNA of rat neurons in cerebral ischemia-reperfusion injury. Acta Pharmacol Sin 2000; 21:1193-6. [PMID: 11603299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023] Open
Abstract
AIM To observe the protective effect of gypenosides (GP) on the neurons of hippocampus, cerebral cortex, corpus striatum, and dentate gyrus in cerebral ischemia-reperfusion injury of rats. METHODS Modified 4-vessel occlusion (4-VO) method was used to establish the model of acute global ischemia. The acridine orange (AO) staining method was used to observe the DNA and RNA contents of cerebral ischemia-reperfusion injury model in the areas. RESULTS The fluorescent intensity (reflecting DNA and RNA contents) of the DNA and RNA in the areas of cerebral ischemia-reperfusion injury was markedly abated compared with the normal control group. In the group of ig GP (100 mg/kg) it was enhanced compared with the model group and was the same as the normal control group. CONCLUSION The injury of the DNA and RNA in the areas of ischemia-reperfusion model was decreased by GP.
Collapse
Affiliation(s)
- G Qi
- Department of Pharmacology, Medical College of CPAPF, Tianjin 300162, China
| | | | | | | | | |
Collapse
|
46
|
Abstract
This study addresses the visualization of crack locations in bone-cement material using a three-dimensional acoustic emission source location technique. Computer software based on an earthquake location technique was developed to determine AE source locations and was used to investigate material cracks formed at the tip of a notch in bone cement. The computed locations show that the cracks form linear features with dimensions between 0.1 and 0.2 mm although larger linear features (almost 3.5 mm) also are present. There is a difference of about 2.5 mm between the average of the event locations, and the location of the tip of the notch is 2.5 mm, which may be due to the finite size of the sensors (5 mm in diameter).
Collapse
Affiliation(s)
- G Qi
- Department of Mechanical Engineering, Engineering Science 320, The University of Memphis, Memphis, Tennessee 38152-6576, USA.
| | | | | |
Collapse
|
47
|
Abstract
This article addresses acoustic emission (AE) wave attenuation in acrylic bone cement and wave attenuation due to the existence of material interface between acrylic bone cement and sawbone. In this article, a series of tests were performed using standard pencil lead break sources. The attenuation features inside acrylic bone cement and sawbone materials and the attenuation due to the existence of material interfaces such as cement-cement and cement-sawbone were studied. In addition, the discrete wavelet-based signal energy decomposition method was introduced to examine detail breakdown of signal energy distribution of attenuation. From the tests, it was observed that the attenuation of AE signal was linear with respect to the wave travel distance for both energy and amplitude. Furthermore, AE energy attenuation was more sensitive than AE amplitude attenuation. In the analysis of attenuation due to material interfaces, the couplant plays a major role in reducing the attenuation at the interfaces. The attenuation at an interface composed by different material is less compared with an interface composed by the same material.
Collapse
Affiliation(s)
- G Qi
- Department of Mechanical Engineering, University of Memphis, Memphis, Tennessee 38152-6576, USA
| |
Collapse
|
48
|
Xu C, Chen B, Wang W, Tian Y, Zhao H, Jiang B, Gao B, Qin S, Yue M, Qi G. Detecting residual ischemia and identifying coronary artery disease after myocardial infarction using dobutamine technetium-99m-MIBI SPECT. Chin Med J (Engl) 2000; 113:579-83. [PMID: 11776021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023] Open
Abstract
OBJECTIVE To evaluate dobutamine technetium-99m methoxy isobutyl nitrile (sestamibi) single-photon emission computed tomography (Dobu-ECT) in detecting residual ischemia and identifying coronary vessel disease after myocardial infarction. METHODS Sixty-two patients with confirmed myocardial infarction were studied with Dobu-ECT at the time of coronary artery angiography. Dobutamine was administered intravenously in incremental rates from 5 to 40 micrograms.kg-1.min-1 at 3-minute intervals. At the highest infusion rate, 7.4 x 10(8) Bq 99mTc-MIBI was injected intravenously, and tomographic imaging was performed after one hour. Resting images were taken after 24 hours, with a second dose of 99mTc-MIBI. RESULTS The sensitivity of Dobu-ECT in detecting residual ischemia of myocardial infarction was 76%, which was higher than dobutamine electrocardiography (Dobu-ECG). Regardless of the single-, double- or triple-vessel diseases, Dobu-ECT was superior to Dobu-ECG in identifying residual ischemia (56% vs 4%, 86% vs 27%, 100% vs 47%, P < 0.01, respectively). The incidence of residual ischemia in patients receiving thrombolytic therapy was 67%, lower than patients without thrombolysis (72%) or those with an old myocardial infarction (94%). But the differences were not statistically significant. Dobu-ECT detected only 56% of ischemias in non-infarct related myocardium. Eighty-two percent of all significantly stenosed vessels were detected with Dobu-ECT, and 84% of patients with multivessel disease could be accurately identified. The sensitivity of Dobu-ECT was significantly greater for detecting severe stenosis over moderate stenosis. The sensitivity for detecting stenosis in the right coronary artery was greater than left anterior descending or left circumflex, but its specificity was lower. CONCLUSION Dobu-ECT can identify residual ischemia, as well as its location and extent after myocardial infarction. Dobu-ECT can also accurately detect significantly stenosed vessels.
Collapse
Affiliation(s)
- C Xu
- Department of Cardiology, People's Hospital, Beijing Medical University, Beijing 100044, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Abstract
CONTEXT As the world's largest producer and consumer of tobacco products, China bears a large proportion of the global burden of smoking-related disease and may be experiencing a tobacco epidemic. OBJECTIVE To develop an evidence-based approach supporting tobacco control initiatives in China. DESIGN AND SETTING A population-based survey consisting of a 52-item questionnaire that included information on demographics, smoking history, smoking-related knowledge and attitudes, cessation, passive smoke exposure, and health status was administered in 145 disease surveillance points in the 30 provinces of China from March through July 1996. PARTICIPANTS A nationally representative random sample of 128766 persons aged 15 to 69 years were asked to participate; 120298 (93.8%) provided data and were included in the final analysis. About two thirds of those sampled were from rural areas and one third were from urban areas. MAIN OUTCOME MEASURES Current smoking patterns and attitudes; changes in smoking patterns and attitudes compared with results of a previous national survey conducted in 1984. RESULTS A total of 41187 respondents smoked at least 1 cigarette per day, accounting for 34.1% of the total number of respondents, an increase of 3.4 percentage points since 1984. Current smoking continues to be prevalent among more men (63%) than women (3.8%). Age at smoking initiation declined by about 3 years for both men and women (from 28 to 25 years). Only a minority of smokers recognized that lung cancer (36%) and heart disease (4%) can be caused by smoking. Of the nonsmokers, 53.5% were exposed to environmental tobacco smoke at least 15 minutes per day on more than 1 day per week. Respondents were generally supportive of tobacco control measures. CONCLUSION The high rates of smoking in men found in this study signal an urgent need for smoking prevention and cessation efforts; tobacco control initiatives are needed to maintain or decrease the currently low smoking prevalence in women.
Collapse
Affiliation(s)
- G Yang
- Chinese Academy of Preventive Medicine and Chinese Association on Smoking and Health, Beijing
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Qi G, Zeng D, Liu L, Zhao A, Xu P. [The effects of Xuezhikang on neointimal proliferation and C-myc gene expression after angioplasty in rabbits]. Zhonghua Nei Ke Za Zhi 1999; 38:514-6. [PMID: 11798686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
OBJECTIVE To investigate the effects of Xuezhikang (XZhK) on the neointimal proliferation and C-myc gene expression after angioplasty in rabbits. METHODS Angioplasty for atherosclerotic stenosis of celiac arteries was performed in 30 male white rabbits after being fed with cholesterol-supplemented diet for 8 weeks, which were then randomized to control group, high-cholesterol group and XZhK group. After 4 weeks, the local vessels were collected for morphological observation. C-myc mRNA level was measured with RT-PCR and C-myc protein with immunohistochemical analysis. RESULTS Morphological observation showed that the neointimal area in the XZhK group were less than the control group (P < 0.05), and that in control group were less than that in the high-cholesterol group (P < 0.05). The levels of C-myc mRNA measured with RT-PCR and the percentage of C-myc protein positive cell by immunohistochemical analysis were lower in the XZhK group than in the control and high-cholesterol group (P < 0.05), The levels in the latter two groups showed no difference (P > 0.05). CONCLUSION XZhK can inhibit the neointimal proliferation and the expression of C-myc gene after angioplasty in rabbits.
Collapse
Affiliation(s)
- G Qi
- Department of Cardiology, The First Affiliated Hospital of China Medical University, Shenyang 110001
| | | | | | | | | |
Collapse
|